NVCT Stock Overview
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nuvectis Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.82 |
| 52 Week High | US$18.65 |
| 52 Week Low | US$6.20 |
| Beta | 0.27 |
| 1 Month Change | -22.06% |
| 3 Month Change | -16.73% |
| 1 Year Change | -50.86% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 109.85% |
Recent News & Updates
Recent updates
Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Jan 06
Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Oct 03We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
Jan 31Nuvectis Pharma forms scientific advisory board for research and development of drugs
Sep 28Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04
Aug 05Nuvectis Pharma declines 13%, announces $15.9M private placement
Jul 27We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
May 04Shareholder Returns
| NVCT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | -4.7% | -3.7% |
| 1Y | -50.9% | -2.7% | 20.2% |
Return vs Industry: NVCT underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: NVCT underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| NVCT volatility | |
|---|---|
| NVCT Average Weekly Movement | 14.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NVCT's share price has been volatile over the past 3 months.
Volatility Over Time: NVCT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 13 | Ron Bentsur | www.nuvectis.com |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company’s lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases.
Nuvectis Pharma, Inc. Fundamentals Summary
| NVCT fundamental statistics | |
|---|---|
| Market cap | US$119.41m |
| Earnings (TTM) | -US$22.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.4x
P/E RatioIs NVCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$22.26m |
| Earnings | -US$22.26m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NVCT perform over the long term?
See historical performance and comparison